Skip to content

Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Baylor S&W

Post Market Observational Study of ESId (MDW Hematology Parameter) for Early Sepsis Detection in the Emergency Department (US Hospitals) and Potential Reduction in Time to Antibiotics - Baylor Scott & White Medical Center

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04291417
Enrollment
1700
Registered
2020-03-02
Start date
2019-11-20
Completion date
2020-06-17
Last updated
2021-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Disease, Emergency Department, Sepsis, Severe Sepsis

Brief summary

The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in earlier decision to administer antibiotics from time of ED presentation for sepsis patients (simulated primary endpoint), with concomitant reductions in length of stay and in-hospital mortality for those patients (secondary endpoints).

Detailed description

The objective of this study is to develop a method for identifying sepsis patients from electronic health records (EHR) based on Sepsis-2 criteria. Sepsis patients will be identified using a Sepsis Definition which includes meeting SIRS score of ≥2 within 12 hours of ED presentation and any microbial testing ordered within 24 hours of ED presentation. The patient will be enrolled if it meets the Sepsis Definition and additional EMR data elements will be extracted to complete case report form. Furthermore, objectives include to confirm the clinical validity and performance of MDW in a control population of sepsis patients where MDW is measured but not reported to physicians. This study is an observational study which will simulate the decision impact of MDW on sepsis identification and patient management.

Interventions

MDW measurement used to detect sepsis. Results will not be used to manage patients.

Sponsors

Beckman Coulter, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* Adult (18 to 89 years) * All race and ethnicities * Presenting to the emergency department with suspicion of infection * Whose assessment includes a CBC with differential * Meets EMR Sepsis Definition

Exclusion criteria

* Pregnancy * Prisoners * Transfers from other ED * Previously enrolled

Design outcomes

Primary

MeasureTime frameDescription
Potential reduction of Time to Antibiotics12 hrs after ED presentationValidate MDW's ability to reduce time to first antibiotics ordered by physician (decision to treat)-Simulated

Secondary

MeasureTime frameDescription
Performance12 hrs after ED presentationValidate MDW's ability to identify incidence of patients diagnosed as Sepsis vs Non-Sepsis, including SIRS and milder forms of infection (non-SIRS) meeting Sepsis EMR definition of \>=2 SIRS criteria within 12 hours of ED presentation and any microbial testing collected within 24 hours of triage in the ED

Other

MeasureTime frameDescription
Health & Economic Benefits for Time to Antibiotics - Simulated12 hrs after ED presentationDetermine MDW's ability to potentially reduced hospital stay using a simulated economic model.
Health & Economic Benefits for Hospital Stay - Simulated12 hrs after ED presentationDetermine MDW's ability to potentially reduced ICU stay, if applicable, using a simulated economic model.
Health & Economic Benefits for Mortality - Simulated12 hrs after ED presentationDetermine MDW's ability to potentially reduced hospital morality, if applicable, using a simulated economic model.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026